Free

CTAF Meeting: Hereditary Angioedema

Event Information

Share this event

Date and Time

Location

Location

California Endowment Oakland Conference Center

2000 Franklin Street

Oakland, CA 94612

View Map

Event description

Description

The California Technology Assesment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on October 25, 2018 to consider the comparative clinical effectiveness and value of long-term prophylaxis for hereditary angioedema (HAE) with lanadelumab and C1 inhibitors.

HAE is a rare genetic disorder characterized by recurrent episodes of tissue swelling in various parts of the body, including the face, hands, feet, airways, and intestinal tract. HAE affects patients’ physical and mental health, with patients reporting significantly poorer health-related quality of life and high rates of depression and anxiety.

ICER will be evaluating the following therapies: lanadelumab (Shire), Haegarda® (CSL Behring), Cinryze® (Shire), and Ruconest® (Pharming) for long-term prophylaxis for HAE.

A list of key dates for stakeholder engagement opportunities and other important information associated with the review of long-term prophylactic therapies for HAE can be found on ICER's website at https://icer-review.org/topic/hereditary-angioedema/.

Share with friends

Date and Time

Location

California Endowment Oakland Conference Center

2000 Franklin Street

Oakland, CA 94612

View Map

Save This Event

Event Saved